CMC Flexibilities for Developing Human Cellular and Gene Therapy Products for Biologics License Application
In the past, the Food and Drug Administration (FDA) had issued several guidances that provide Chemistry, Manufacturing and Controls (CMC) recommendations to sponsors developing Human Cellular and Gene Therapy (CGT) products for biologics license applications (BLAs) under Title 21 of the Code of Federal Regulations (CFR) Part 601 Licensing (for Biologics). On May 5, 2026, the Food and Drug Administration released their final guidance for “Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for Biologics License Application”. Sponsors developing CGT products should consider the CMC recommendations in this guidance in addition to those guidances for industry, as applicable. This guidance provides information on when CMC flexibilities may be appropriate for the development of CGT products and does not comprehensively address the CMC information and data necessary to support CGT product licensure under section 351 of the Public Health Service Act (42 U.S.C. 262) [1] . In short, the FDA is providing how it may accept practical, risk-based, flexible alternatives to “traditional” manufacturing and testing expectations for CGT products heading towards the BLA regulatory pathway.
How does this impact other industries outside of non-CGT? For those working in medical devices, traditional drug manufacturing, or human cells, tissues, and cellular and tissue-based products (HCT/Ps), the ideas here are increasingly “industry-wide”. FDA is reinforcing a lifecycle mindset (controls maturing over time) and the Agency is encouraging scientifically justified alternatives when the classic high volume validation playbook doesn’t fit.
Quick recap of CGT, BLA, and CMC:
CGT (Human Cellular and Gene Therapy) are therapies that deliver genes/genetic material and/or use living cells as treatment.
BLA (Biologics License Application) is the regulatory pathway for submissions to the FDA requesting permission to market a biological product in the United States.
CMC (Chemistry, Manufacturing, and Controls) are the “how it’s made and controlled” evidence such as materials, process, testing, and specifications. These items show a company can reliably produce a product that is safe, pure, and potent.
“Flexibilities” are where the FDA may accept practical alternatives to traditional datasets when those expectations are not feasible for CGT (if the sponsor provides a strong scientific and risk-based justification).
Sponsors are encouraged to consider flexible, phase appropriate strategies throughout development with early engagement with FDA to tailor approaches. To meet licensure requirements for safety, purity, and potency, sponsors may adopt non-traditional methods suited to the product’s nature, manufacturing process, and development stage. The extent of data and flexibility depends on the product’s complexity, manufacturing knowledge, and stage of development; additional data may be requested case-by-case.
Flexibilities During Clinical Development
Use phase-appropriate current good manufacturing practice (CGMP) standards. For early phases, manufacturing may be exempt from full CGMP, focusing on establishing safety rather than efficacy. Develop release criteria aligned with clinical phase, allowing more permissive standards early on, with refinement as experience grows and amount of collected data increases. Employ risk-based comparability assessments for manufacturing changes, accepting limited data for minor, low-risk modifications, especially when product attributes are maintained. Leverage prior knowledge, such as platform analytical methods, process validation data, and experience with similar products, to streamline development and reduce testing burdens. Utilize voluntary consensus standards to enhance predictability and reduce documentation.
Process Validation Flexibilities
Develop a scientifically justified process performance qualification (PPQ) strategy, with flexibility on the number of batches required. This strategy should be based on understanding, process complexity, and control measures. Allow for concurrent release of PPQ batches post-licensure, provided they meet specifications and are within shelf life, supporting expedited distribution and clinical use.
Commercial Specification Flexibilities
When minimal lots are available at BLA submission, develop release specifications that balance product quality with practical constraints, refining them over time with post-approval manufacturing data. Use a scientifically supported validation approach, including possibly validating analytical methods with a single representative lot, if justified. Post-approval, consider reevaluating and updating acceptance criteria based on manufacturing experience, with changes submitted as supplements to prior approval documentation.
Additional Flexibilities
Leverage stability data from clinical or commercial lots, or similar products, to support expiration dating, with appropriate data to justify shelf life.
Seek exceptions from retaining reserve samples when lot sizes are very small or individualized.
Use alternative analytical methods to traditional compendial tests, especially rapid or proprietary technologies, if validated to meet accuracy, sensitivity, and reproducibility standards, facilitating faster release and microbiological control.
These flexibilities aim to address the unique challenges of CGT products, including small batch sizes, complex manufacturing, and limited material, while maintaining product quality and safety.
Overall, the guidance promotes early and ongoing communication with FDA, advocates for a science and risk-based, flexible regulatory framework that adapts to the complexities of CGT products, facilitating innovation and timely patient access while ensuring product quality and safety. Sponsors should be sure to reach out to their dedicated review division to facilitate this ongoing communication.
Thanks for stopping by! Keep checking back as we continue following industry trends. If you need any assistance on this, reach out here!
Reference